SCHEMBL6022956

SCHEMBL6022956

CCCCCCCCCOc1cc(C(=O)C=CN2CCN(CC(O)c3ccc(C)cc3)CC2)cc(OCCCCCCCCC)c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
PKM P14618 1/20 0.37
SMPD1 P17405 4/20 0.37
TSHR P16473 1/20 0.36
ADRA1D P25100 3/20 0.35
ADRA1A P35348 3/20 0.35
ADRA1B P35368 3/20 0.35
ADRB2 P07550 2/20 0.35
ADRB1 P08588 2/20 0.35
ADRB3 P13945 2/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
IGF1R P08069 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023884 0.96 SPHK1 (0.41) SPHK1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL6022920 0.92 KDM4E (0.39) SPHK1KDM4EKMT2AIGF1R
SCHEMBL6023503 0.92 KDM4E (0.39) SPHK1KDM4EKMT2AIGF1R
SCHEMBL6023913 0.91 ADRB2 (0.40) SPHK1ALDH1A1KMT2AMEN1SMPD1
SCHEMBL6023543 0.91 KMT2A (0.40) SPHK1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL6023325 0.89 SPHK1 (0.40) SPHK1KDM4EMAPTIGF1RABCB1
SCHEMBL6023156 0.89 USP2 (0.42) SPHK1ALDH1A1KMT2AMEN1ADRA1D
SCHEMBL6022899 0.89 SPHK1 (0.40) SPHK1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL6022735 0.88 ALDH1A1 (0.40) SPHK1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL6023970 0.86 GRIN2B (0.40) SPHK1ALDH1A1KMT2ANPC1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078407-B2 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-07-18 US claimed
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US claimed
US-7078407-B2 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-07-18 US disclosed
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them HTT, PARK7, NQO1 SPHK1 3832/4885ALDH1A1 804/4885KDM4E 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.